Leading Edge Polymers Exhibited at Booth # 2074
AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a
leading developer of advanced polymer materials for a broad range of
medical devices announced today that it will be showcasing its
innovative technology at the world's largest medical OEM event --
Medical Design & Manufacturing (MD&M West) -- that will take place
February 10-12 at the Anaheim Convention Center in California.
“As a comprehensive resource for the medical device community, MD&M West
is a key venue for informing medical device companies and OEM
manufacturers about AdvanSource Biomaterials’ performance polymers and
the targeted end-product optimization they deliver. We will be
showcasing our new product extensions, specifically our newly expanded
solution-based polymer capabilities as well as our antimicrobial
enhancement lines. We are excited by the opportunities our new market
driven product lines provide and the opportunity to continue broadening
our range of capabilities to meet the medical industry’s evolving
material needs,” noted Vice President Sales and Marketing Khristine
Carroll.
In addition to Ms. Carroll, AdvanSource President Michael Adams, Dr.
Andrew Reed, Vice President of Science and Technology and members of the
marketing and R&D teams, will be at booth # 2074 to demonstrate the
Company’s leading edge technology, notably products such as ChronoFlex®,
HydroMed™, and HydroThane™ which have been developed to
overcome a wide range of design and functional challenges, from the need
for dimensional stability, ease of manufacturability and demanding
physical properties to overcoming environmental stress cracking (ESC)
and providing heightened lubricity for ease of insertion.
The Company will also showcase its antimicrobial extension lines
that compliment the ChronoFlex® and HydroMed™ product families. Through
proprietary manufacturing techniques, the Company has produced materials
which allow for full homogenous dispersion throughout the polymer, thus
resulting in long lasting and consistent activity and the prevention of
leaching. The end result being a technologically advanced antimicrobial
material which reduces the potential for foreign body patient
infections, has a higher kill rate and is less susceptible to bacterial
growth and biofilm formations. AdvanSource has developed a drug-free,
antimicrobial technology targeting the minimization of MRSA, among other
clinical infections associated with medical devices.
About AdvanSource Biomaterials Corporation
AdvanSource Biomaterials Corporation manufactures advanced polymer
materials which provide critical characteristics in the design and
development of medical devices. The Company’s biomaterials are used in
devices that are designed for treating a broad range of anatomical sites
and disease states. AdvanSource’s business model leverages its
proprietary materials science technology and manufacturing expertise in
order to expand its product sales and royalty and license fee income.
The Company is conducting a clinical trial for regulatory approval at
two sites in Europe for its CardioPass™ synthetic coronary bypass graft.
More information about AdvanSource is available at its website: www.advbiomaterials.com
AdvanSource Biomaterials
Khristine Carroll, 978-657-0075
VP
Sales & Marketing
info@advbiomaterials.com
or
CardioTech
International, Inc.
Eric Walters, 978-657-0075
Vice President
& CFO
general-info@cardiotech-inc.com
or
Press
Sylvia
Dresner, 212-616-6161
Senior Vice President
VMW Corporate &
Investor
Relations
